Navidea Biopharmaceuticals Announces Centers for Medicare & Medicaid Services Issuance of Lymphoseek® Reimbursement Pass-Through C Code, Effective as of October 1, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a Healthcare Common Procedure Coding System (HCPCS) Pass-Through “C Code”, for Lymphoseek (technetium Tc 99m tilmanocept) Injection. Navidea anticipates that the billing code, which will become effective on October 1, 2013, will streamline the billing and reimbursement process for hospital providers who use Lymphoseek and support its fair and equitable reimbursement. Lymphoseek was approved by the U.S. Food and Drug Administration in March 2013 for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.

Help employers find you! Check out all the jobs and post your resume.

Back to news